Immunocytochemical demonstration of down regulation of HLA class-I molecule expression in human metastatic breast carcinoma

Clinical and Experimental Metastasis

Volumn 21, Issue 3, 2004, Pages 243-249

  Saio, Masanao ^a   Teicher, Matt ^b   Campbell, Gaynor ^b   Feiner, Helen ^b   Delgado, Yara ^b   Frey, Alan B ^c  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NEW YORK UNIVERSITY   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

breast cancer; HLA class I; metastasis

Indexed keywords

HLA ANTIGEN CLASS 1;

ANTIGEN EXPRESSION; ARTICLE; BREAST CARCINOMA; BREAST METASTASIS; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LYMPH NODE;

BREAST NEOPLASMS; DOWN-REGULATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM METASTASIS;

EID: 4344582880     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:CLIN.0000037707.07428.ff     Document Type: Article

References (13)

1. Ogmundsdottir HM, Petursdottir I and Gudmundsdottir I Interactions between the immune system and breast cancer. Acta Oncol 1995; 34: 647-50.
2. Ogmundsdottir HM Immune reaction to breast cancer: for better or for worse? Arch Immunol Ther Exp (Warsz) 49 2001; S75-81.
3. Hicklin DJ, Marincola FM and Ferrone S. HLA class-I antigen down-regulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 1999; 5: 178-86.
4. Levin I, Klein T, Goldstein J, Kuperman O, Kanetti J and Klein B. Expression of class-I histocompatibility antigens in transitional cell carcinoma of the urinary bladder in relation to survival. Cancer 1991; 68: 2591-4.
5. Zia A, Schildberg FW and Funke I. MHC class-I negative phenotype of disseminated tumor cells in bone marrow is associated with poor survival in R0M0 breast cancer patients. Int J Cancer 2001; 93: 566-70.
6. Concha A, Cabrera T, Ruiz-Cabello F and Garrido F. Can the HLA phenotype be used as a prognostic factor in breast carcinomas? Int J Cancer Suppl 1991; 6: 146-54.
7. Wintzer HO, Benzing M and von Kleist S. Lacking prognostic significance of beta 2-microglobulin, MHC class-I and class-II antigen expression in breast carcinomas. Br J Cancer 1990; 62: 289-95.
8. Ruiz-Cabello F, Lopez Nevot MA, Gutierrez J et al. Phenotypic expression of histocompatibility antigens in human primary tumours and metastases. Clin Exp Metast 1989; 7: 213-26.
9. Goepel JR, Rees RC, Rogers K et al. Loss of monomorphic and polymorphic HLA antigens in metastatic breast and colon carcinoma. Br J Cancer 1991; 64: 880-3.
10. Maiorana A, Cesinaro AM, Fano RA and Collina G. Expression of MHC class-I and class-II antigens in primary breast carcinomas and synchronous nodal metastases. Clin Exp Metast 1995; 13: 43-8.
11. Kaklamanis L, Leek R, Koukourakis M et al. Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class-I molecules in metastatic versus primary breast cancer. Cancer Res 1995; 55: 5191-4.
12. Vitale M, Rezzani R, Rodella L et al. HLA class-I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res 1998; 58: 737-42.
13. Sykulev Y, Joo M, Vturina I et al. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T-cell response. Immunity 1996; 4: 565-71.